BR112017007769A2 - compostos e composições para modulação de atividades de cinase de egfr mutante - Google Patents

compostos e composições para modulação de atividades de cinase de egfr mutante

Info

Publication number
BR112017007769A2
BR112017007769A2 BR112017007769-8A BR112017007769A BR112017007769A2 BR 112017007769 A2 BR112017007769 A2 BR 112017007769A2 BR 112017007769 A BR112017007769 A BR 112017007769A BR 112017007769 A2 BR112017007769 A2 BR 112017007769A2
Authority
BR
Brazil
Prior art keywords
compounds
compositions
provides
protein kinase
present
Prior art date
Application number
BR112017007769-8A
Other languages
English (en)
Other versions
BR112017007769B1 (pt
Inventor
Suh Byung-Chul
Devidas Salgaonkar Paresh
Lee Jaekyoo
Sung Koh Jong
Song Ho-Juhn
Yong Lee In
Lee Jaesang
Sik Jung Dong
Kim Jung-Ho
Kim Se-Won
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55654993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of BR112017007769A2 publication Critical patent/BR112017007769A2/pt
Publication of BR112017007769B1 publication Critical patent/BR112017007769B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

resumo ?compostos e composições para modulação de atividades de cinase de egfr mutante? a presente invenção fornece um novo grupo de inibidores proteína de cinase, derivados de aminopirimidina, e sais farmaceuticamente aceitáveis destes que são úteis para tratar doença proliferativa de célula e transtorno tal como câncer e doença imune. a presente invenção fornece métodos para sintetizar e administrar os compostos inibidores da proteína cinase. a presente invenção também fornece formulações farmacêuticas compreendendo pelo menos um dos compostos inibidores da proteína cinase junto com um portador, diluente ou excipiente farmaceuticamente aceitável, portanto. a invenção também fornece intermediários úteis gerados durante as sínteses dos derivados de aminopirimidina.
BR112017007769-8A 2014-10-13 2015-10-13 Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos BR112017007769B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063394P 2014-10-13 2014-10-13
US62/063,394 2014-10-13
PCT/KR2015/010784 WO2016060443A2 (en) 2014-10-13 2015-10-13 Compounds and compositions for modulating egfr mutant kinase activities

Publications (2)

Publication Number Publication Date
BR112017007769A2 true BR112017007769A2 (pt) 2018-01-16
BR112017007769B1 BR112017007769B1 (pt) 2023-10-10

Family

ID=55654993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007769-8A BR112017007769B1 (pt) 2014-10-13 2015-10-13 Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos

Country Status (25)

Country Link
US (1) US9593098B2 (pt)
EP (3) EP3604294B1 (pt)
JP (3) JP6524221B2 (pt)
KR (4) KR102208775B1 (pt)
CN (2) CN106795144B (pt)
AU (1) AU2015331166B2 (pt)
BR (1) BR112017007769B1 (pt)
CA (1) CA2962914C (pt)
CY (2) CY1122737T1 (pt)
DK (2) DK3207035T3 (pt)
ES (2) ES2879474T3 (pt)
HR (2) HRP20200201T1 (pt)
HU (2) HUE048006T2 (pt)
LT (2) LT3604294T (pt)
MX (3) MX2017003181A (pt)
NZ (1) NZ730012A (pt)
PH (1) PH12017500488A1 (pt)
PL (2) PL3207035T3 (pt)
PT (2) PT3207035T (pt)
RS (2) RS61865B1 (pt)
RU (2) RU2727700C2 (pt)
SG (1) SG11201701960XA (pt)
SI (2) SI3604294T1 (pt)
TW (2) TWI664173B (pt)
WO (1) WO2016060443A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
MX2018013413A (es) 2016-05-26 2019-06-06 Zeno Royalties & Milestones Llc Compuestos inhibidores de egfr.
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
BR112019025836A2 (pt) * 2017-06-13 2020-07-07 Beijing Adamadle Biotechnology Limited Liability Company composto de aminopirimidina, método de preparação do mesmo e uso do mesmo
MA49703A (fr) * 2017-07-28 2021-04-21 Yuhan Corp Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
RS64654B1 (sr) * 2017-07-28 2023-10-31 Yuhan Corp Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
SG11201913556SA (en) * 2017-07-28 2020-02-27 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
WO2019042187A1 (zh) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN108017633A (zh) * 2018-01-30 2018-05-11 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN108047207A (zh) * 2018-01-30 2018-05-18 天津大学 N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. AMINOPYRIMIDINE COMPOUND USED TO INHIBIT PROTEIN KINASE ACTIVITY
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
SG11202110376XA (en) * 2019-03-19 2021-10-28 Voronoi Inc Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
MA55508A (fr) 2019-03-29 2022-02-09 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CN110128354A (zh) * 2019-06-20 2019-08-16 大连大学 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
KR20210152312A (ko) * 2020-06-08 2021-12-15 주식회사 종근당 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물
AU2021339962A1 (en) 2020-09-14 2023-05-25 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
WO2022131741A1 (ko) * 2020-12-14 2022-06-23 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
CN117255792A (zh) * 2021-05-07 2023-12-19 沃若诺伊公司 杂芳基衍生物、其制备方法以及包括其作为活性成分的药物组合物
KR102607051B1 (ko) * 2021-05-17 2023-11-30 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
EP4349835A1 (en) 2021-06-01 2024-04-10 Hangzhou Solipharma Co., Ltd. Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
KR20230054567A (ko) 2021-10-15 2023-04-25 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
US20240116926A1 (en) 2022-04-28 2024-04-11 Astrazeneca Ab Heteroaromatic compounds
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429222A (zh) * 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
MXPA05005547A (es) * 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
JP4428565B2 (ja) 2004-10-05 2010-03-10 東京エレクトロン株式会社 処理液塗布装置
US20070072894A1 (en) 2005-03-24 2007-03-29 Kempf J V Synthesis of pyrroloquinoline quinone (PQQ)
JP5007029B2 (ja) 2005-07-13 2012-08-22 Ntn株式会社 グリース組成物および該グリース封入転がり軸受
AU2006283935A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag Fused pyrazole as p38 MAP kinase inhibitors
JP2007117465A (ja) 2005-10-28 2007-05-17 Sharp Corp 集塵器およびそれを備えた電気掃除機
WO2007111471A1 (en) 2006-03-29 2007-10-04 Ktfreetel Co., Ltd. Digital device and method for providing additional service by using the same
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
ES2711249T3 (es) 2008-06-27 2019-04-30 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US8629132B2 (en) * 2009-11-13 2014-01-14 Genosco Kinase inhibitors
AU2012221927B2 (en) * 2011-02-25 2016-04-28 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
PL3686194T3 (pl) * 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
PL2804861T3 (pl) 2012-01-20 2018-08-31 Genosco Podstawione związki pirymidyny i ich zastosowanie jako inhibitory SYK
WO2014040555A1 (zh) * 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
ES2792979T3 (es) * 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
WO2015188777A1 (en) * 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用

Also Published As

Publication number Publication date
CN106795144A (zh) 2017-05-31
AU2015331166A1 (en) 2017-03-30
PL3604294T3 (pl) 2021-11-02
CN111686110A (zh) 2020-09-22
PT3207035T (pt) 2020-02-19
RS61865B1 (sr) 2021-06-30
RU2727700C2 (ru) 2020-07-23
JP2019163277A (ja) 2019-09-26
ES2879474T3 (es) 2021-11-22
CA2962914A1 (en) 2016-04-21
AU2015331166B2 (en) 2018-04-26
EP3604294A1 (en) 2020-02-05
TW201619150A (zh) 2016-06-01
KR102487451B1 (ko) 2023-01-11
JP2017530999A (ja) 2017-10-19
ES2770058T3 (es) 2020-06-30
KR20210011068A (ko) 2021-01-29
CY1124359T1 (el) 2022-07-22
KR20170066650A (ko) 2017-06-14
RS59900B1 (sr) 2020-03-31
MX2021010761A (es) 2022-06-09
RU2017116598A (ru) 2018-11-21
JP2020196740A (ja) 2020-12-10
US9593098B2 (en) 2017-03-14
TWI664173B (zh) 2019-07-01
MX2020002168A (es) 2021-09-07
HRP20210949T1 (hr) 2021-09-03
US20160102076A1 (en) 2016-04-14
KR20230010836A (ko) 2023-01-19
EP3604294B1 (en) 2021-05-05
CA2962914C (en) 2018-10-23
LT3207035T (lt) 2020-02-25
HRP20200201T1 (hr) 2020-05-15
KR102073854B1 (ko) 2020-02-05
KR20200014944A (ko) 2020-02-11
HUE048006T2 (hu) 2020-05-28
CN106795144B (zh) 2020-06-16
TW201938553A (zh) 2019-10-01
RU2017116598A3 (pt) 2018-11-21
LT3604294T (lt) 2021-07-26
CN111686110B (zh) 2023-06-16
SG11201701960XA (en) 2017-04-27
SI3207035T1 (sl) 2020-04-30
DK3207035T3 (da) 2020-01-27
NZ730012A (en) 2019-06-28
MX2017003181A (es) 2017-07-20
SI3604294T1 (sl) 2021-08-31
EP3929190A1 (en) 2021-12-29
EP3207035A2 (en) 2017-08-23
PT3604294T (pt) 2021-07-29
PH12017500488A1 (en) 2017-07-31
PL3207035T3 (pl) 2020-06-01
BR112017007769B1 (pt) 2023-10-10
JP6524221B2 (ja) 2019-06-05
WO2016060443A2 (en) 2016-04-21
CY1122737T1 (el) 2021-03-12
WO2016060443A3 (en) 2016-06-23
RU2020123547A (ru) 2020-08-18
HUE054848T2 (hu) 2021-09-28
DK3604294T3 (da) 2021-06-28
JP6754864B2 (ja) 2020-09-16
EP3207035B1 (en) 2019-11-20
EP3207035A4 (en) 2018-03-14
KR102208775B1 (ko) 2021-01-28
TWI730331B (zh) 2021-06-11
KR102662358B1 (ko) 2024-04-30

Similar Documents

Publication Publication Date Title
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112018070549A2 (pt) degradantes de proteína mdm2
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
CY1121444T1 (el) Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων
BR112016029662A2 (pt) compostos de heteroaril para inibição de quinase
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
MX2013013294A (es) Inhibidores de tirosina-cinasas.
BR112012010085A2 (pt) inibidores de quinases
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
BR112017009651A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
EA201790838A1 (ru) Ингибитор киназы aurora a
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
TR201819805T4 (tr) Flavaglin türevleri̇.
EA202191192A1 (ru) Кристаллические соли ингибитора плазменного калликреина
EA201792676A1 (ru) Ингибиторы jak1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014950-5 PROTOCOLO 870230065320 EM 25/07/2023 18:38.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2015, OBSERVADAS AS CONDICOES LEGAIS